News

The Novo Nordisk Foundation and Temasek Foundation today announced a co-funded grant of 2 million Singapore dollars (1.3 million EUR) to the National University of Singapore (NUS) Yong Loo Lin School of Medicine, to support DETECT-Asia (Strengthening Diagnostics for sEvere bacTErial infeCTions in Asia), a programme led by ADVANCE-ID (ADVANcing Clinical Evidence in Infectious Diseases)—a clinical research network based at NUS, which involves over 100 hospitals in Asia. This programme directly supports our international mission to combat AMR and improve global health outcomes, and we look forward to working with Temasek Foundation, NUS Medicine, and other partners to strengthen infectious disease research and innovation across Asia. Dr Lee Fook Kay, Head, Pandemic Preparedness, Temasek Foundation, added: "At Temasek Foundation, we are committed to advancing healthcare innovation and resilience across Asia. With the Novo Nordisk Foundation and NUS Medicine, we seek to build up and link our hospitals to get faster and better data and testing by sharing through DETECT-Asia. With the support of the Novo Nordisk Foundation and Temasek Foundation, we are well-positioned to further enhance the regional capacity, data, and collaborations needed to strengthen pandemic resilience and transform infectious disease management in Asia." Looking ahead This initiative represents the first step in building regional leadership in infectious disease research, strengthening Asia's role in shaping global health innovation, and creating lasting impact for patients and communities across the region."